Navigation Links
MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research
Date:8/12/2008

area to launch this effort.

"The completion of these two agreements establishes the scientific foundation of the company and firmly set us on a research and development pathway that we hope will address a significant unmet medical need by preventing recurrence in certain types of cancers and prolonging patient survival," said David Hansen, the company's President and Chief Executive Officer. Philip Livingston, M.D., the company's Chief Science Officer and co-founder of MabVax added, "Targeting residual circulating cancer cells and micrometastasis with passively administered or vaccine induced antibodies against multiple targets is an approach well suited to eradicating the cancer cells that cause metastatic disease. Our clinical trials over the next several years will tell us a great deal about the utility of this approach to treating cancer."

About MabVax Therapeutics, Inc.

MabVax was formed to commercialize the work of Dr. Phil Livingston and colleagues at Memorial Sloan-Kettering Cancer Center (MSKCC) who over the last 25 years have developed monovalent cancer vaccines against ten distinct antigenic targets on various types of cancer cells. These vaccines target gangliosides and other carbohydrate antigens that are the most extensively expressed antigenic targets on the cell surface of certain cancers. Vaccines, or passively administered antibodies developed from these vaccines, produced evidence demonstrating the prevention of tumor recurrence and prolonged survival in preclinical models and supporting data in early Phase I human clinical trials. The company is initially focused on developing polyvalent vaccines and a pipeline of fully human monoclonal antibodies to address a variety of cancers including sarcoma, small cell lung cancer, and melanoma. MabVax closed a Series A venture financing with GBP Capital in late February 2008.


'/>"/>
SOURCE MabVax Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Alimera Sciences, Inc. (NASDAQ: ALIM ... research, development and commercialization of prescription ophthalmic pharmaceuticals, announced ... from Hercules Technology Growth Capital, Inc. (NYSE: ... final advance under the Loan and Security Agreement that ... , Alimera Sciences Limited, entered into with Hercules in ...
(Date:9/30/2014)... 30, 2014 A study using a relatively ... new look at the composition of carotid artery disease ... and treat the disease, a leading cause of stroke. ... Lexington between September 2010 and May 2012, was featured ... of the American College of Cardiology (JACC) Cardiovascular Interventions. ...
(Date:9/30/2014)... , Sept. 30, 2014 Valeant Pharmaceuticals International, ... today announced that the company,s Bridgewater, New ... the U.S. Food and Drug Administration (FDA) relating to ... with regards to Sculptra Aesthetic injectable, which was divested ... to the management of Valeant,s contract manufacturers (rather than ...
Breaking Medicine Technology:Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2
(Date:9/30/2014)... Hospice & Palliative Care of ... gala, honoring three outstanding individuals for their commitment ... provide extraordinary and dignified comfort, care and compassion ... life-limiting illness. , The event was held at ... recognized William (Bill) J. McGuinness, Director of Tiffany ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Dr. Karl ... knee pain program of care that is dramatically ... , His clinic—Johnson Chiropractic Neurology & Nutrition—applies a proprietary, ... knee. It also addresses sources of inflammation, neurology of ... the “neurokinetic chain” from the brain to the spine, ...
(Date:9/30/2014)... WASHINGTON (Sept. 30, 2014) Levothyroxine is considered the ... and a new review of therapies for the condition ... not altered that assessment, say a team of investigators.,1Their ... journal Thyroid , finds insufficient consistent data exist ... whether generic, or sold under various trade names, such ...
(Date:9/30/2014)... IL (PRWEB) September 30, 2014 Healthcare ... at the National Association of Health Advocacy Consultants (#NAHAC) ... Healthcare Advocacy” (#NAHAC14) to be held October 30th - ... its debut at NAHAC14: Standards and Best Practices for ... grows into a profession, advocates have needed a set ...
(Date:9/30/2014)... September 30, 2014 Market Research ... is a professional and in-depth market survey on ... reviews the basic information of Cialis including its ... explores global and China’s top manufacturers of Cialis ... market share etc. , The report further analyzes ...
Breaking Medicine News(10 mins):Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3Health News:New guidelines for treatment of hypothyroidism endorse current therapy 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 2Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 3Health News:Cialis Industry (CAS 171596-29-5) Global and Chinese Analysis for 2014-2019 Now Available at LifeScienceIndustryResearch.com 4
... , TUESDAY, March 1 (HealthDay News) -- A ... hospitals for sepsis -- a potentially life-threatening bacterial infection in ... those treated at other hospitals. Researchers analyzed data from ... sepsis between June 2004 and June 2006. In total, there ...
... over time been able to show that medicine designed ... serious diseases such as cancer. However, now research also ... part in the drug delivery process. "Researchers ... of viruses. The nanoparticles are effective for drug delivery ...
... ATLANTA March 1, 2011 A new report from ... the 141,000 cases and 49,000 deaths from colorectal cancer ... prevented by increasing the use of established screening tests ... The report, Colorectal Cancer Facts & Figures 2011-2013, released ...
... Invasive plant species have long had a reputation as being ... Stan Harpole, assistant professor of ecology, evolution and organismal biology ... of more than 70 researchers working at 65 sites worldwide ... it is true that problematic invasive species often spread widely ...
... Los Angeles, CA (February 28, 2011) Eating more tomatoes ... the risk of conditions such as cancer, osteoporosis and ... American Journal of Lifestyle Medicine , (published by SAGE). ... tomatoes and tomato products than any others. Researchers Britt ...
... , TUESDAY, March 1 (HealthDay News) -- For ... to relieve symptoms and result in major improvements in ... Up to 20 percent of women in their childbearing ... Not all fibroids cause symptoms, but some patients experience ...
Cached Medicine News:Health News:Hospital Spending Doesn't Affect Sepsis Survival Rates 2Health News:Research provides new findings on drug delivery with nanoparticles 2Health News:New report says large proportion of colorectal cancer deaths could be prevented 2Health News:Global ISU study: Invasive species widespread, but not more than at home range 2Health News:Health benefits of eating tomatoes emerge 2Health News:Uterine Fibroid Treatments Seem to Boost Quality of Life 2
... Focus from Thermo Labsystems was designed specifically ... Advanced features such as the new fast ... on microvolumes help to define this as ... The new interchangeable handle plate offers a ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: